JPRN-jRCT2031200409
Recruiting
未知
Special drug use-results surveillance of Tabrecta Tablets (MET exon 14 skipping mutation-positive unresectable advanced/recurrent non-small cell lung cancer)
Sugimoto Toshiya0 sites100 target enrollmentMarch 11, 2021
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- MET exon 14 skipping mutation-positive unresectable advanced/recurrent non-small cell lung cancer
- Sponsor
- Sugimoto Toshiya
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All patients receiving Tabrecta for MET exon 14 skipping mutation\-positive unresectable advanced/recurrent NSCLC during a specified post\-marketing period
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Post-marketing Surveillance Protocol Number; CDRB436I1401BRAF V600E mutation-positive unresectable advanced or recurrent solid tumorJPRN-jRCT2031230623sato masayuki90
Completed
Not Applicable
Special Drug Use-results Surveillance of Tabrecta TabletsNon-small Cell Lung CancerNCT04575025Novartis Pharmaceuticals109
Recruiting
Not Applicable
Special drug use-results surveillance <Patients with cold agglutinin disease>Cold agglutinin diseaseJPRN-UMIN000049607sanofi K.K.100
Unknown
Not Applicable
Drug use surveillance of Takecab for Supplement to Helicobacter pylori eradicatioThe following diseases in patients for whom H. pylori will be eradicated with triple therapy: Gastric ulcer, duodenal ulcer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, idiopathic thrombocytopenic purpura, stomach following endoscopic treatment of early gastric cancer, or H. pylori gastritisJPRN-jRCT1080222951TAKEDA PHARMACEUTICAL COMPANY LTD.500
Recruiting
Not Applicable
Special Drug Use Results Surveillance for the use of Odefsey in pregnant womeHIV/AIDSJPRN-UMIN000034028Janssen Pharmaceutical K.K.3